“Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma,” states D. Ryan Ormond, MD, Ph.D, Neurosurgery, University of Colorado.
What does Dr. Ormond say about the continued use of Depo-Provera after meningioma resection, published in the Journal of Neuro-oncology in 2018?
“Compared to patients taking combination or estrogen-only contraception, those taking progesterone-only contraception demonstrated a greater recurrence rate (33.3 vs. 19.6%) with a reduced time to recurrence (18 vs. 32 months, p = 0.038) … those taking progesterone-only contraception.”
Read D. Ryan Ormond, MD, Ph.D.’s article.
Greg Vigna, MD, JD, national Depo-Provera attorney, states, “We represent women, many of whom experienced recurrence after continuing Depo-Provera use following meningioma resection. A Dear Doctor Letter warning of this risk could have prevented this harm, particularly given that some physicians do not remain current with the medical literature. Dr. Ormond clearly identifies a subpopulation of women at significant risk, and a Dear Doctor Letter would have significantly reduced the likelihood of recurrence associated with continued Depo-Provera use after meningioma resection. Instead, we now represent women who suffered recurrent meningiomas due to ongoing Depo-Provera use, resulting in combined medical malpractice claims against the prescribing physicians and product liability claims against Pfizer.
Dr. Vigna continues, “In his article, Dr. Ormond cited a 2006 study by Wigertz that reported an increased relative risk of meningiomas associated with subdermal implants, injections, and hormonal intrauterine devices. Depo-Provera, subdermal implants, and hormonal intrauterine devices are all progestins. For twenty years, Pfizer took no action to investigate this safety signal while women across the world developed meningiomas and recurrent meningiomas.”
Watch Dr. Vigna’s educational episode on Justice with Dr. V for an in-depth look at the association of Depo-Provera and Meningiomas: https://youtu.be/08n0qssgZfU?si=TtebqjOM6qgHvGCK
Click here to watch Dr. Vigna’s episode on Justive with Dr. V to learn more about meningioma risk with Depo-Provera.
Watch Justice with Dr.V on TikTok to learn more about Depo-Provera.
Dr. Vigna is a California and Washington D.C., lawyer and is Co-Counsel with the Ben Martin Law Group, a national pharmaceutical injury law firm in Dallas, Texas. The attorneys are product liability and medical malpractice attorneys who represent women who have suffered meningiomas and have cases filed across the country, including in the California Superior Court in Alameda County.
Learn more: https://vignalawgroup.com/practice-area/meningioma-resection/
California Offices:
8939 S. Sepulveda Blvd., Suite 102, Los Angeles, CA 90045
2570 N. First Street, 2nd Floor, San Jose, CA 95131
931 10th Street, #962, Modesto, CA 95354
2281 Lava Ridge Court, Suite 200, Roseville, CA 95661
600 West Broadway, Suite 700, San Diego, CA 92101
Connecticut Office:
515 Centerpoint Drive, Suite #2212, Middletown, CT 06457
8939 S. Sepulveda Blvd. Suite 102
Los Angeles, CA, 90045
Dr. Greg Vigna, is the principal of Greg Vigna, MD, JD, PLC, a California personal injury law firm, and his law firm has a non-exclusive referral relationship with the attorneys listed within this site. Dr. Vigna, co-counsels with attorneys across the country.